Lepu Biopharma Co

Lepu Biopharma Co EBIT

The EBIT of Lepu Biopharma Co (2157.HK) as of Nov 5, 2026 is 101.77 M CNY. In the previous year, EBIT was -405.88 M CNY — a change of -125.07% (higher).

EBIT

101.77 MCNY

YoY

-125.07%

Last updated:

In 2025, Lepu Biopharma Co's EBIT was 101.77 M CNY, a -125.07% increase from the -405.88 M CNY EBIT recorded in the previous year.

The Lepu Biopharma Co EBIT history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT
Date
EBIT
Jan 1, 2021
-1.18 B CNY
Jan 1, 2022
-820.03 M CNY
Jan 1, 2023
4.80 M CNY
Jan 1, 2024
-405.88 M CNY
Jan 1, 2025
101.77 M CNY
Jan 1, 2026 (e)
101.20 M CNY
Jan 1, 2027 (e)
320.05 M CNY
Jan 1, 2028 (e)
638.36 M CNY
The Lepu Biopharma Co EBIT history
YEAREBITYoY
est638.36 MCNY+99.46%
est320.05 MCNY+216.24%
est101.20 MCNY-0.56%
101.77 MCNY-125.07%
-405.88 MCNY-8,562.78%
4.80 MCNY-100.58%
-820.03 MCNY-30.22%
-1.18 BCNY+94.03%
-605.70 MCNY+14.45%
-529.22 MCNY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Lepu Biopharma Co Revenue

Lepu Biopharma Co Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2021
0.00 CNY
-1.18 B CNY
-1.18 B CNY
Jan 1, 2022
18.13 M CNY
-820.03 M CNY
-802.07 M CNY
Jan 1, 2023
225.35 M CNY
4.80 M CNY
-22.10 M CNY
Jan 1, 2024
367.79 M CNY
-405.88 M CNY
-411.38 M CNY
Jan 1, 2025
1.06 B CNY
101.77 M CNY
296.36 M CNY
Jan 1, 2026 (e)
1.13 B CNY
101.20 M CNY
76.36 M CNY
Jan 1, 2027 (e)
1.62 B CNY
320.05 M CNY
286.36 M CNY
Jan 1, 2028 (e)
2.38 B CNY
638.36 M CNY
591.82 M CNY

Lepu Biopharma Co Margins

Lepu Biopharma Co stock margins

The Lepu Biopharma Co margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Lepu Biopharma Co. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Lepu Biopharma Co.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2021
80.39 %
- %
- %
Jan 1, 2022
87.12 %
-4,524.03 %
-4,424.94 %
Jan 1, 2023
87.45 %
2.13 %
-9.81 %
Jan 1, 2024
79.66 %
-110.35 %
-111.85 %
Jan 1, 2025
80.39 %
9.60 %
27.96 %
Jan 1, 2026 (e)
80.39 %
8.95 %
6.75 %
Jan 1, 2027 (e)
80.39 %
19.80 %
17.71 %
Jan 1, 2028 (e)
80.39 %
26.82 %
24.86 %

Lepu Biopharma Co Stock analysis

What does Lepu Biopharma Co do? Lepu Biopharma Co., Ltd. generates revenue through the development and commercialization of oncology therapeutics, including antibody drug conjugate (ADC), oncolytic virus, and immunotherapy products at clinical and pre-clinical stages. The company's major pipeline assets, MRG003, MRG002, HX008, and LP002, are sold domestically in China via dedicated sales forces and internationally through partnerships. Strategic collaborations strengthen in-house R&D and manufacturing capabilities, supporting the commercialization of its pipeline products. The firm focuses on tumor candidate drugs, targeting both domestic and international markets with its key clinical-stage drug candidates. Lepu Biopharma's revenue streams come from the sale of its pipeline products, with MRG003, MRG002, HX008, and LP002 being the primary assets driving commercialization. The company leverages in-house manufacturing and strategic partnerships to expand its market reach, selling products in China through dedicated sales and marketing teams and internationally via partnerships. Its oncology-focused portfolio includes antibody drug conjugate (ADC), oncolytic virus, and immunotherapy products, which are developed through internal R&D and collaborations. The company's business model centers on combining in-house research and development with strategic collaborations to develop a market differentiating pipeline. Products like MRG003, MRG002, HX008, and LP002 are commercialized domestically in China and internationally through partnerships, targeting both the domestic and global oncology markets. Lepu Biopharma's revenue is derived from the sale of these pipeline assets, with a focus on tumor candidate drugs in clinical and pre-clinical stages. Lepu Biopharma Co is one of the most popular companies on Eulerpool.

EBIT Details

Analyzing Lepu Biopharma Co's EBIT

Lepu Biopharma Co's Earnings Before Interest and Taxes (EBIT) represents the company's operating profit. It is calculated by deducting all operating expenses, including the cost of goods sold (COGS) and operating expenses, from the total revenue, but before accounting for interest and taxes. It provides insights into the company’s operational profitability, excluding the impacts of financing and tax structures.

Year-to-Year Comparison

A yearly comparison of Lepu Biopharma Co's EBIT can reveal trends in the company’s operational efficiency and profitability. An increase in EBIT over the years can indicate enhanced operational efficiency or growth in revenue, while a decrease might raise concerns about increased operating costs or declining sales.

Impact on Investments

Lepu Biopharma Co's EBIT is a significant metric for investors. A positive EBIT suggests that the company is generating enough revenue to cover its operating expenses, an essential aspect for assessing the company’s financial health and stability. Investors closely monitor EBIT to gauge the company’s profitability and potential for future growth.

Interpreting EBIT Fluctuations

Fluctuations in Lepu Biopharma Co’s EBIT can be due to variations in revenue, operating expenses, or both. An increasing EBIT indicates improved operational performance or increased sales, while a declining EBIT can signal rising operational costs or reduced revenue, prompting a need for strategic adjustments.

Frequently Asked Questions about Lepu Biopharma Co stock

EBIT of Lepu Biopharma Co is 101.77 M CNY in 2025.

EBIT of Lepu Biopharma Co changed from -405.88 M CNY to 101.77 M CNY, representing a -125.07% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBIT Lepu Biopharma Co since 2006 – with annual values, charts, and detailed analysis.

"Earnings before interest and taxes", abbreviated as EBIT, is also referred to as the operating result of a company. It is a key figure that allows the profit to be assessed over a specific period of time, usually a fiscal year. Taxes and interest are not deducted from EBIT, making it suitable for international comparisons of different companies.

Net income
+ Tax expense
+ Interest expense and other financial expenses
- Interest income and other financial income
= EBIT (operating profit)

EBIT's CNY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBIT's Lepu Biopharma Co historically and in real time.

The sales revenue is important for evaluating a stock.

EBIT is an acronym for "Earnings Before Interest and Tax" and represents a company's gross profit before taxes and interest are deducted. The EBIT amount is often used as a metric to evaluate a company.

History

The EBIT was originally introduced in the 1940s when the US Internal Revenue Service (IRS) passed a new tax law. This law required companies to calculate their profit before deducting taxes and interest on loans (or "interest and taxes"). Since then, the EBIT has been used as one of the key financial indicators in evaluating a company.

Usage

The EBIT can be used to assess a company by comparing its financial results to a benchmark or a comparative value. The EBIT is also used to determine how much the company's shareholders will receive from its operating income.

Calculation

EBIT is calculated by deducting taxes and interest on loans from the company's net profit. This amount can be calculated in various ways, but the most common method is as follows:

EBIT = Net profit + interest and taxes

Example: Eulerpool: Your source for quantitative stock data At Eulerpool, we are dedicated to providing you with comprehensive and accurate stock information. Our website offers a wide range of tools and features, including charts, stock lists, and more. Whether you are an experienced investor or just starting out, our platform is designed to meet your needs. With our in-depth analytics and algorithms, you can make informed decisions and stay ahead of the market. Explore our extensive collection of stocks, track their performance, and access real-time data. With Eulerpool, you can easily navigate the world of finance and monitor the stocks that matter to you. Join our community today and gain valuable insights into the world of stocks and investments. Sign up for free and discover the power of Eulerpool. Stay informed. Stay ahead. Eulerpool - your trusted partner in stock data.
Net profit of XYZ Co. = $1,000,000
Interest and taxes = $ 500,000
EBIT of XYZ Co. = $1,500,000

Application

The EBIT value is often used to determine and evaluate the financial stability of a company. The EBIT value can also be used to determine how much money a company can spend on investments or dividends.

Use of EBIT in stock investment

Investors use EBIT to determine if a stock is over- or undervalued. If a company has a high EBIT value, it may indicate that its stock is overvalued, as the profit it generates could be lower than what it would generate with a different stock.

Advantages of EBIT

EBIT is a helpful measure for determining the financial stability of a company. There are several advantages associated with using EBIT, such as:
- EBIT eliminates the impact of financing on the company's earnings.
- It is a useful measure for determining the profits that a company can distribute to its shareholders.
- It can be used to determine whether a stock is overvalued or undervalued.

Disadvantages of EBIT

There are also some disadvantages to using EBIT, such as:
- EBIT cannot be used as the sole measure to evaluate a company as it does not reflect the overall profit of the company.
- EBIT can be influenced by unforeseen events such as a tax increase.
- EBIT is not always a reliable indicator of a company's future profit development.

Conclusion

The EBIT is an important measure used to evaluate a company. It can be used to determine how much money a company can generate from its operational results and whether a stock is overvalued or undervalued. However, the EBIT also has some disadvantages as it does not reflect the overall profitability of a company and can be influenced by unforeseen events. Therefore, it is important to consider the EBIT in conjunction with other financial indicators to obtain a complete picture of the company.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Lepu Biopharma Co

All Key Metrics — Lepu Biopharma Co